Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	348.84	316.89	444.09	281.59	202.13	402.71
Depreciation & Amortization	101.34	88.05	81.31	84.86	49.64	3
Stock-Based Compensation	57.53	51.57	43.39	36.62	24.4	20.82
Other Adjustments	16.65	347.31	-0.45	24.17	52.39	-130.07
Change in Receivables	-151.44	-128.06	-74.25	-3.34	-83.94	6.76
Changes in Inventories	30.52	2.55	-67.38	-26.88	-17.48	7.37
Changes in Accounts Payable	-27.93	6.21	46.99	-12.55	24.54	1.17
Changes in Unearned Revenue	-	-	-	-	-2.49	-0.75
Changes in Other Operating Activities	-37.07	-32.96	5.36	4.1	-9.06	-11.56
Operating Cash Flow	677.42	651.56	479.06	388.57	240.11	299.44
Operating Cash Flow Growth	34.45%	36.01%	23.29%	61.83%	-19.81%	439.98%
Capital Expenditures	-9.76	-6.97	-10.7	-15.29	-4.81	-1.46
Sale of Property, Plant & Equipment	-	-	-	-	26.01	-
Purchases of Investments	-116.56	-247.36	-647.6	-292.91	-255.21	-652.52
Proceeds from Sale of Investments	681.08	722.25	395.57	211.3	746.13	247.68
Payments for Business Acquisitions	0.71	-1,014	-	-	-999.12	-
Investing Cash Flow	-458.27	-545.81	-262.72	-96.91	-487.01	-406.29
Short-Term Debt Issued	-	-	-	-	120	-
Short-Term Debt Repaid	-	-	-	-	-120	-
Long-Term Debt Issued	-	1,470	-	-	250	784.88
Long-Term Debt Repaid	-	-763.39	-	-13.48	-327.45	-369.06
Net Long-Term Debt Issued (Repaid)	-	706.61	-	-13.48	-77.45	415.81
Issuance of Common Stock	19.62	21.83	31.14	7.88	14.05	12.54
Repurchase of Common Stock	-190.63	-342.37	-250	-392.38	-200	-350.06
Net Common Stock Issued (Repurchased)	-171.01	-320.54	-218.86	-384.5	-185.95	-337.52
Other Financing Activities	-	-471.24	-	-	625.78	-0.42
Financing Cash Flow	-83.47	-85.17	-218.86	-407.99	362.37	77.87
Net Cash Flow	135.68	20.57	-2.52	-116.33	115.48	-28.98
Free Cash Flow	667.65	644.59	468.37	373.28	235.3	297.98
Free Cash Flow Growth	3.58%	37.62%	25.47%	58.64%	-21.04%	462.76%
FCF Margin	44.26%	46.15%	46.13%	45.01%	35.65%	67.22%
Free Cash Flow Per Share	5.48	5.20	3.62	2.78	1.67	2.03
Levered Free Cash Flow	405.94	1,080	499.68	302.34	165	816.29
Unlevered Free Cash Flow	411.91	375.22	495.17	307.13	257.57	444.86

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q